Fosfomycin Is the Only Oral Option Left, and It Was Never Approved for This
A single patient, on her fourth resistant urinary tract infection in six months with one oral option left. The disagreement isn't about which drug her organism is susceptible to — it's about whether a lower-certainty, lower-burden treatment is the right call for a specific 81-year-old, not urinary tract infections in general.
Constance A., an 81-year-old woman who spent her career as a reference librarian and still walks to the corner market most mornings, has lived alone since her husband died four years ago, is on her fourth urinary tract infection in six months, each one a slightly worse version of a pattern that started with occasional dysuria and has progressed to two emergency visits for fever and flank pain. Her most recent culture grew an E. coli resistant to nitrofurantoin, trimethoprim-sulfamethoxazole, every oral beta-lactam tested, and ciprofloxacin — susceptible only to fosfomycin and to intravenous carbapenems. She has no structural abnormality on prior imaging, no diabetes, and lives independently enough that her daughter, who calls her every evening, is the only regular check on how she's actually managing day to day; a fall two winters ago, resolved without lasting injury, is the closest thing to a red flag in an otherwise stable functional history.
Fosfomycin is FDA-approved only as a single 3-gram dose for uncomplicated cystitis, not for the complicated, recurrent picture Constance actually has, which means any use here is off-label by definition — a real gap, not a technicality, since the drug's approved evidence base doesn't describe her situation at all. Derington and colleagues, in a 2020 Open Forum Infectious Diseases retrospective, followed 171 episodes of multi-dose oral fosfomycin used off-label for complicated UTI in exactly this outpatient setting — most often one 3-gram dose every three days, for a mean total duration of about six days — and found clinical resolution in 67.3% of episodes, a real number but a meaningfully imperfect one, and one drawn from retrospective data rather than a randomized trial. The alternative, outpatient parenteral ertapenem through a PICC line, has a far stronger evidence base for treating resistant gram-negative infections generally, but asks an 81-year-old living alone to manage a central line — its own infection risk, its own fall risk if it catches on something, its own daily flush routine — for a course of treatment measured in weeks rather than days.
At a discharge-planning visit
After four recurrences in six months, I want the option with the strongest evidence behind it. Ertapenem is reliably active against her organism, and outpatient parenteral therapy for resistant gram-negative infections has a much more direct evidence base than off-label fosfomycin dosing does. I'd rather treat this definitively than reach for our least-studied option first.
'Least-studied' undersells what we actually have. Derington et al.'s 2020 Open Forum Infectious Diseases retrospective followed 171 episodes of multi-dose oral fosfomycin used exactly this way — outpatient, off-label, for complicated UTI — most commonly one 3-gram dose every three days for about six days total, and found clinical resolution in 115 of them, 67.3%. That's real evidence for this specific use, not a guess extrapolated from the single-dose approval.
And the comparison you're implying has actually been run. A 2022 multicentre retrospective in the same journal put 110 fosfomycin patients against 212 on ertapenem for outpatient complicated UTI, most of them ESBL producers resistant to every other oral option — the adjusted odds ratio for clinical success at thirty days was 1.21, with a confidence interval straddling one in both directions. That isn't fosfomycin winning. But it means the gap you're describing between a well-evidenced drug and a poorly-evidenced one hasn't shown up when someone measured it head-to-head in her population.
I'm still not claiming it beats ertapenem — retrospective data can't carry that — I'm saying the efficacy argument is thinner than 'strongest evidence' makes it sound, which changes what the burden question has to outweigh.
I want to name what neither of you has weighed yet: Constance lives alone, checks in with her daughter only by phone each evening, and had a fall two years ago. A PICC line means a real infection risk, a real catch-and-fall risk, and a daily flush routine she'd be managing herself. That's not a small cost next to a 'more definitive' treatment — for her specifically, it's a concrete burden that deserves the same weight as the efficacy numbers, not less.
Agreed: start multi-dose oral fosfomycin today, with a repeat urine culture at day 7 to confirm resolution and a clear plan to move to ertapenem via PICC without delay if it fails.
Not agreed, and named explicitly as an open values question rather than a settled clinical answer:
The geriatrician's weighting of her living situation will have been the deciding factor that spared her a PICC line, without a randomized trial ever needing to settle whether fosfomycin "really" works as well as ertapenem in general.
The infectious disease physician's preference for the more definitively evidenced option from the start will have been the more protective call, at the cost of one additional week without effective treatment while fosfomycin was tried first.